secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001867096-25-000031
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris appoints Dr. Anh Nguyen as CMO; Ken Johnson retiring April 1, 2025
------------------------------------------------------------------------

- Dr. Anh Nguyen named Chief Medical Officer effective Feb 24, 2025.
- Ken Johnson, SVP Global Dev & Medical Affairs, to retire April 1, 2025.
- Nguyen will lead Medical, Regulatory, Preclinical/Clinical Dev, Pharmacovigilance.
- Nguyen previously served as program medical lead for Gvoke NDA/MAA at Xeris.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000031/0001867096-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000031/xers-20250224.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer